COP31 participants arriving at the sprawling venue on the fringes of Antalya by taxi and shuttle. The real-life challenges of curbing fossil fuel emissions are palpable in the daily logistics of getting to and from the venue.

ANTALYA – The first draft of COP31’s main political decision includes a standalone paragraph on the accelerating risks of climate change to human health, setting up a potentially big symbolic victory for advocates who have fought for years to win a place for health inside the UN climate process.

“Climate change is already harming human health, including physical and mental health, through climate-sensitive diseases such as malaria, dengue and cholera, heat stress, maternal health, food and nutrition insecurity and damage to health facilities during extreme events,” the draft states.

The text also “underlines” the need to strengthen the climate resilience of health systems by including health in national adaptation and climate plans, and by integrating climate information and early warning systems into public health protection.

The paragraph sets no targets, commits no funding and asks governments to do nothing specific. Its two verbs, “recognises” and “underlines”, sit at the bottom of the UN’s diplomatic vocabulary, signalling acknowledgement rather than action.

Beyond that clause, health appears in four of the draft’s other 143 paragraphs, each time linked to another issue: as a benefit of climate action, in early warning systems, in human rights language, and in services for children.

Negotiations in Antalya are due to close on Friday, and, in a tradition duly respected by every COP since 2003, are likely to run overtime. The decision text – and health’s inclusion in it – will be up for debate until the final gavel, and many paragraphs are likely to be pruned as countries draw red lines.

The COP31 presidency said in a note accompanying the draft that the text is “not intended to reflect consensus”. Every element remains open, Türkiye and Australia said, “including whether they should be included at all”.

“Nothing will come out of the negotiations except for a vaguely worded statement,” a Swedish observer to the negotiations told Health Policy Watch, adding: “The parties are just too entrenched in their opposing positions.”

Co-benefits across the text

The flagship item of COP31 host Turkiye’s summit agenda has the potential to generate significant health co-benefits, but faces steep opposition.

Elsewhere, the draft includes proposals with large potential health gains not directly framed as health measures.

The text calls on countries to help raise electricity’s share of global energy use to 35% by 2035, a headline target of Türkiye’s voluntary Action Agenda. Electrifying transport, industry and buildings would cut the fuel burning behind much of the world’s air pollution, which kills around 8 million people every year.

Despite its status as the flagship initiative of the Turkish presidency, it faces steep opposition to inclusion in the final decision. The Arab Group has opposed top-down targets for energy and other sectors in the talks, and the African Group has rejected electrification targets that come without money to meet them, according to the Earth Negotiations Bulletin.

On record opposition to the target means it remains to be seen if the ‘greener’ references in the draft text to “accelerating the clean energy transition through increased clean electrification” and “tripling renewable energy capacity” will survive the final days of negotiations – even if only as purely voluntary declarations of intent.

Other ambitious clauses with major potential health benefits are also in the draft but face long odds of making the final cut, particularly those on phasing out fossil fuels and the subsidies that support them.

The draft’s call for “accelerated action to phase out fossil fuels, including through the immediate transition away from fossil fuels in energy systems” is likely to be struck down before the summit closes. Oil-producing states forced phase-out language out of the Dubai deal in 2023, and at COP30 the Arab Group called any text targeting sectors of their economies “off the table”. The final Belém decision made no mention of fossil fuels.

The draft also “emphasises the importance of phasing out inefficient fossil fuel subsidies that do not address energy poverty or just transitions, as soon as possible”, repeating commitments made in Glasgow and Dubai. With the Iran war driving up fuel prices, global fossil fuel subsidies are projected to exceed $1 trillion this year, according to the UN Development Programme.

The WHO’s own economic case for climate action rests heavily on cutting those subsidies, a Health Policy Watch analysis found. In a report released days before the summit, WHO estimated that six climate policies could prevent 1.6 million deaths a year, yet some 1.2 million of those depend on removing fossil fuel subsidies and raising taxes on coal, oil and gas. The draft addresses only “inefficient” subsidies, and says nothing about taxing fossil fuels.

More health references, but few hooks for action

References to health in the draft COP31 decision.

Health advocates were still heartened by the increased references to health in the climate text compared to previous years. However, they stressed that this was only a first step in light of the millions of lives impacted by the  “global health emergency” caused by the climate crisis that many in the health world are calling on WHO to declare.

“Basically my impression is that there’s a lot of health coverage included in the current draft of the cover text but no hook for health to be more prominent in future negotiations or decisions to be implemented by countries,” said WHO’s Elena Villalobos, who leads ATACH, a strategic alliance to support health sector responses to climate change.

“The most important issue is related to commitments by parties to consider public health implications of all their adaptation and mitigation policies and programs – although all parties to the UN Climate Convention already agreed to these commitments, and they still are not being implemented nor reported.  So we need a mechanism for that,”  she added.

See related story:

Call for New WHO Instrument to Address Climate-Driven Global Health Emergency 

Health not among the issues publicly raised by countries

Health was not among the issues countries publicly raised in the oral consultations on the cover decision, according to the presidency’s summary of them, meaning no country is on public record as sponsoring the health content of the text. Its inclusion suggests requests on health were added through written submissions, which are not published publicly. 

Beyond the standalone paragraph, health appears in four of the draft’s other 143 paragraphs, each time linked to another issue: as a benefit of climate action, in early warning systems, in human rights language, and in services for children.

Negotiations in Antalya are due to close on Friday. As is tradition with every COP since 2003, they are likely to run overtime. The decision text will be up for debate until the final gavel, and many paragraphs are likely to be pruned as countries draw red lines. 

The COP31 presidency said in a note accompanying the draft that the text is “not intended to reflect consensus”, and was drafted with “an inclusive approach to reflect the breadth of views expressed by Parties”. Every element remains open, Türkiye and Australia said, “including whether they should be included at all”.

New health initiatives launched at COP31 draw few pledges and less finance

Health initiatives launched at UN Climate Conferences since 2021.

The potential for a breakthrough inclusion in COP31’s final decision threatens to be overshadowed by the minimal support that has accompanied other health-related initiatives in Antalya.

The Antalya Initiative for Resilient Health Systems, the flagship presidency health initiative launched by Türkiye with the World Health Organization (WHO) at the summit’s opening Health Day, has yet to announce any participating countries, staff or funding. 

No government pledged new money for climate and health that day, the third consecutive COP without fresh government financing for health.

A second new pledge, a political declaration on a “healthy transition” led by Spain, had six signatories as of Tuesday out of nearly 200 countries at the talks: Spain, France, Peru, Tuvalu, Ireland and Barbados.

The declaration names fossil fuels as the main driver of climate change’s threat to health and as the cause of “millions of preventable deaths”. It commits signatories to use the public, economic and political influence of the health sector to drive action, and asks WHO “to lead the global effort to address the public health imperative of transitioning away from fossil fuels, as it did in the past with other harmful substances such as tobacco and alcohol”.

“The best clinical practice is one that integrates environmental perspectives in clinical decisions,” said Javier Padilla, Spain’s secretary of state for health, who spearheaded the declaration. “Putting the focus on the energy transition from the health perspective is an intelligent way to approach climate change.”

The declaration, and its minimal uptake, is the kind of outcome WHO Director-General Tedros Adhanom Ghebreyesus warned at the outset of the summit would not be enough.

Declarations “do not protect people,” Tedros told health ministers gathered in a sparse conference room on COP31’s Health Day on the opening day of the conference, 9 November. “Implementation does.” See related story:

‘Declarations Do Not Protect People’: COP31 Opens Under Pressure to Deliver Results Over Words

Building momentum

A declaration on Climate and Health at COP28 in Dubai drew the most signatories of any, with 148 countries, but little follow-up in subsequent years.

Nothing agreed or announced in Antalya so far pays for that implementation.

The movement on health at COP31 builds on a patchwork of voluntary frameworks and initiatives launched alongside the UN climate talks since Glasgow, with varying levels of support. The most concrete is WHO’s Alliance for Transformative Action on Climate and Health (ATACH), launched at Glasgow in 2021, whose 106 member countries commit to building climate-resilient, low-carbon health systems.

The COP28 Declaration on Climate and Health in Dubai, a broad statement of intent, drew the most signatures of any, with 148 countries.

COP29 in Baku produced a coalition of five past and incoming summit presidencies pledging to keep health on the COP programme, outside the formal negotiations.

The Belém Health Action Plan, the most detailed of all, has 40 signatories so far, up from 33 when it was announced at the close of COP30 last year. 

Implementation absent from mounting pile of plans 

Top health and climate officials gather at a high-level ministerial meeting on COP31’s Health Day.

But while declarations and initiatives have launched, the money to act on them has yet to follow. In a WHO survey last year, more than 90% of countries named insufficient finance as a top barrier to their health and climate plans, Tedros said in his Health Day comments.

Multilateral climate funds have directed about 2% of adaptation finance and 0.5% of all their climate finance to health since 2004, according to a 2025 analysis by the Berlin-based think tank adelphi, roughly the share WHO reported at Glasgow. The Green Climate Fund, the UN’s largest climate fund, had financed a single health project in Malawi, as of COP29.

On Health Day, Brazil’s health minister Alexandre Padilha said international public commitments for health adaptation fell from about $3.2 billion in 2022 to $2.2 billion in 2024. 

He also launched a “financing framework” for the Belém plan, developed with Wellcome and the Rockefeller Foundation, which maps which climate funds, development banks, philanthropies and national budgets could pay for each measure.

“This is not a new fund,” Padilha said of the framework, which he described as “a map”.

The Climate and Health Funders Coalition, a group of more than 35 philanthropies that pledged $300 million in Belém, said it had awarded more than $225 million in its first year and attracted $150 million in new commitments.

“There’s no way that philanthropy can fill the hole or deliver health systems for whole countries,” said Alan Dangour, director of climate and health at Wellcome, a coalition member. “Governments are slow-moving beasts and sometimes require a bit of a nudge.”

“The first thing we can do is provide some technical advice to give you some ideas of what needs to change,” he said. “Then of course finance needs to follow. That is a huge problem.”

No country asked to put health on the agenda

Delegates gather for the opening ceremony of COP31 in Antalya.  No country pressed to have health on the formal negotiating agenda of this year’s conference.

While health may at least get more of a mention in the final text, no country asked to add health to the formal negotiating agenda in Antalya, according to UN meeting records, despite WHO’s calls for health to be part of the negotiations.

“[Health] belongs in the negotiated text,” Tedros told ministers on Health Day. “It should be an explicit eligibility area for climate finance and its share should grow as adaptation finance grows.”

Only governments can propose items for the negotiating agenda, and they must file before a session opens. None of the agendas for COP31, the parallel Paris Agreement meeting or the two technical bodies that prepare their work lists a health item, indicating no country pursued the idea despite WHO’s vocal push. 

With the COP31 agenda adopted on 9 November, the earliest health could gain an item of its own is the June 2027 technical sessions in Bonn or COP32 in Addis Ababa. A government would need to file in time, and no country could object when the agenda is adopted.

While WHO has argued for a dedicated negotiating track, other civil society groups with which Health Policy Watch spoke in Antalya expressed a preference for health to run through existing negotiations, warning that a standalone item could paradoxically cut health out of higher-profile parts of the talks.

One way or another, however, the endgame is the same: more investments in health-related climate action by countries and international actors.

“If health is more prominent, then finance will follow,” said Villalobos.

Image Credits: Fletcher/Health Policy Watch, Dennis Sylvester Hurd, UNFCCC.

A girl receives a measles vaccine in Paraguay.

WASHINGTON – Bolivia, Mexico, and the United States have lost their status as countries that have eliminated measles elimination as a public health risk.

The Pan American Health Organization (PAHO) announced in a press conference that the three countries had all seen sustained continued in-country transmission of the highly contagious virus for at least a year, meaning that they could no longer be certified as measles-free by PAHO, the regional arm of the World Health Organization (WHO). 

In 2016, the Region of the Americas became the first WHO region in the world to be certified as having eliminated endemic measles transmission.  It remained the only region with a measles-free status until 2025, when Canada’s sustained outbreak led to the loss of its elimination status. 

Now, three additional countries have lost their elimination status as well. 

PAHO’s independent Regional Monitoring and Re-Verification Commission for Measles, Rubella and Congenital Rubella Syndrome Elimination (RVC) met 10- 13 November. After reviewing outbreaks in the region from January 2025 – 2026, the RVC recommended elimination status be withdrawn from the three countries. Dr Jarbos Barbosa, PAHO director, said he accepted this recommendation in a briefing to the press Tuesday. 

Bolivia, Mexico, and the US will be asked to submit corrective plans to the Organization outlining how they will tackle their respective outbreaks. 

Since losing its status last year, Canada has since reached several promising milestones in the road back to elimination, including no endemic transmission in 60 days. In its statement today, PAHO urged all  countries to intensify their vaccination efforts.

Highly contagious disease

Measles Bolivia
Measles cases in Bolivia in 2025 by epidemiological week. The country is one of three that sustained endemic transmission of the same genotype for at least a year.

In just one week in early November in 2026, nearly 59,000 people suffered measles infection in the region. By comparison, the same period in 2025 saw 12,740 cases, illustrating the way in which the disease has made a comeback.

In Mexico, cases reached 6,600 in 2025, and 13,800 confirmed cases January – October 2026, per the World Health Organization’s October update. The US experienced 2,288 cases in 2025 and over 5,000 cases so far in 2026. Bolivia’s measles’ outbreak, which has not sickened people at the same magnitude as in Mexico or the US, has steadily circulated since mid 2025. 

Waning vaccination rates and barriers to health care precipitated the explosion of cases of the potentially deadly infection, Barbosa emphasized. 

“The main challenge is the growing number of persons who remain unprotected. Immunization gaps have built up over time, leaving many children, adolescents, and adults susceptible to the disease,” he said. “These gaps are often concentrated in specific geographical areas and communities, creating the conditions for the rapid spread of the virus.”

Barbosa also noted that measles is an incredibly contagious disease: one person can infect up to 18 people, and can cause pneumonia, encephalitis, blindness, or even death. 

Vaccination key to controlling outbreaks

Measles PAHO Barbosa
Dr Jarbos Barbosa on Tuesday announces the PAHO independent panel’s verdict that Bolivia, Mexico, and the United States lost their measles elimination status.

While the US, Mexico, and Bolivia have seen sustained endemic transmission of the same genotype, or strain, of the virus for at least 12 months between January 2025 and January 2026, many other countries in the region are experiencing outbreaks. Guatemala is experiencing a severe outbreak this year, with over 34,000 cases between January and November 2026, per PAHO. 

PAHO noted it was providing direct technical support for the outbreaks in Brazil, Bolivia, Colombia, Guatemala, Honduras, and Peru. 

Dr Daniel Salas, PAHO’s executive manager for the Special Program for Comprehensive Immunization, told media he expected countries – including the US – to intensify their vaccination and surveillance capacities. 

Salas praised how many US states have focused their efforts on under vaccinated communities through enhanced community outreach, culturally appropriate messaging, contact tracing, and catch-up vaccination campaigns. 

Americas could regain its elimination status if it acts resolutely

Barbosa emphasized that the entire region can achieve elimination status once again – but it means that health officials and policymakers need to take continued, resolute action.

“Measles elimination is not a trophy that is won once and placed on a shelf,” said Barbosa. 

“It is an achievement that must be safeguarded every day by closing immunity gaps and ensuring that we reach every community. The path to regaining elimination is clear: achieving and maintaining at least 95% coverage with two doses of the measles vaccine in all communities, supported by robust surveillance and an effective response to outbreaks.”

See related story:

US Stands to Lose Measles Elimination Status as Multiple States Face The Worst Outbreaks in Nearly Three Decades

Image Credits: Pan American Health Organization (PAHO), PAHO.

Hormone-disrupting chemicals cross the placenta into developing fetuses, yet chemical safety testing rarely accounts for pregnancy’s unique biological susceptibility, a joint WHO and UNEP report warns.
Hormone-disrupting chemicals cross the placenta into developing fetuses, yet chemical safety testing rarely accounts for pregnancy’s unique biological susceptibility, a joint WHO and UNEP report warns.

Toxic chemicals cross the human placenta to drive irreversible reproductive and developmental harm, a landmark WHO and UNEP assessment presented at Geneva’s inaugural Global Framework on Chemicals conference warns. Meanwhile, conservative delegations halted a plan to track gender-differentiated exposures and protect female-dominated workforces.

Routine contact with synthetic pollutants is driving widespread reproductive and metabolic disorders across the globe, the first major UN scientific assessment of endocrine-disrupting chemicals in over a decade warns. Synthesising ten years of clinical and toxicological research, the joint report by the World Health Organization (WHO) and the UN Environment Programme (UNEP) was presented on Tuesday.

Scientists reviewed evidence on hundreds of manufactured compounds found in everyday consumer goods, packaging, and industrial plastics. The findings reveal that daily exposure to these substances now imposes global health-related costs exceeding $1.1 trillion every single year.

Mounting clinical evidence links these chemicals directly to falling fertility rates, impaired brain development, and rising rates of reproductive disorders like endometriosis. Researchers also identified direct biological associations with thyroid malfunction, childhood obesity, metabolic liver disease, and hormone-sensitive cancers.

“These effects can be long-lasting and, in some cases, irreversible,” said Sheila Aggarwal-Khan, director of UNEP’s industry and economy division, stressing that unmanaged commercial chemicals pose escalating risks to both human health and wildlife worldwide.

Exposure begins in the womb

Endocrine-disrupting phthalates permeate everyday cosmetics, food packaging, children’s toys, and medical devices, creating pervasive routes of daily human exposure.
Endocrine-disrupting phthalates permeate everyday cosmetics, food packaging, children’s toys, and medical devices, creating pervasive routes of daily human exposure.

Hazardous additives enter the human body before birth through contaminated food packaging, cosmetics, household textiles, and plastics, the report finds.

Plastic additives and compounds such as phthalates and bisphenols cross the placenta, accumulating in fetal tissue before infants take their first breath. These substances can disrupt hormonal development, with the WHO confirming they are routinely detected “in blood, breast milk, and cord blood.”

“Protecting health means preventing harmful exposures before they occur,” said Bruce Gordon, acting director for environment and climate change at the WHO – an approach he called critical for safeguarding pregnant women and future generations.

More than 350,000 industrial chemicals are registered globally, yet only a tiny fraction has ever been screened for hormonal disruption. The vast majority enter commercial supply chains without basic testing for reproductive or developmental toxicity.

Global framework drives stronger regulatory push

Report co-author Laura Vandenberg stresses at Tuesday's forum that scientists already have sufficient evidence to justify immediate restrictions on hormone-disrupting chemicals.
Report co-author Laura Vandenberg (second from left) stresses that scientists already have sufficient evidence to justify immediate restrictions on hormone-disrupting chemicals.

The sobering scientific warnings land as more than 100 governments gather in Geneva for the first conference of the Global Framework on Chemicals from 16 to 20 November. Adopted in Bonn in 2023, the international agreement aims to prevent chemical pollution and phase out the world’s most dangerous industrial substances.

While the framework operates as a voluntary multilateral instrument, it establishes formal targets to overhaul national safety laws and restrict high-risk product ingredients. Delegates are negotiating measurable tracking indicators to hold governments and chemical manufacturers publicly accountable for reducing human exposure.

The framework also establishes dedicated implementation programmes to help developing nations build chemical safety legislation and regulate industrial supply chains. Improving transparency across consumer goods represents a primary objective of the Geneva negotiations, driving voluntary standards to protect human health.

Speaking at the conference’s health and chemicals forum, report co-author Laura Vandenberg warned that existing safety testing regimes fail to protect the public.

“If we were doing a good job at testing, no human would be exposed to something that alters their health,” report co-author Laura Vandenberg told delegates at the conference’s Health and Chemicals Forum – arguing that scientists already hold enough biological evidence to mandate sweeping restrictions without waiting for more data.

To halt generational harm, the report urges governments to mandate pre-market testing and phase out endocrine disruptors across high-contact consumer products.

Dedicated gender plan sparks plenary rift

Workers in female-dominated sectors like textile manufacturing face routine chemical exposures that a stalled UN Gender Action Plan aims to curb.
Workers in female-dominated sectors like textile manufacturing face routine chemical exposures that a stalled UN Gender Action Plan aims to curb.

While the WHO and UNEP report documents broad threats ranging from metabolic disease to wildlife decline, it also warns that chemical protection fails unless policies track sex-specific vulnerabilities and gendered workplace exposures. However, as findings circulated the Geneva conference centre hallways, political tension erupted on the plenary floor.

Negotiators met on Tuesday to debate a dedicated Gender Action Plan designed to track differentiated toxic exposures and protect high-risk workers. The three-year strategy urges governments to collect sex-disaggregated health data and eliminate hazardous chemical exposures in female-dominated sectors such as the textile and healthcare industries. It also seeks to promote equal representation for women in national chemicals management and international environmental decision-making.

Labour and health advocates note that hormone disruptors routinely slip through regulatory nets because toxicological testing historically relied on male biological models. While factors like pregnancy and body fat alter chemical toxicity, gendered divisions of labour dictate daily workplace exposure. Without tracking both biological susceptibility and occupational patterns, advocates warn that chemical protection policies will continue to fail women.

Conservative bloc challenges gender mandate

The United States blocked consensus on the Global Framework on Chemicals Gender Action Plan, demanding the removal of gender terminology from UN texts.
The United States blocked consensus on the Global Framework on Chemicals Gender Action Plan, demanding the removal of gender terminology from UN texts.

However, the proposal triggered immediate ideological resistance from major powers questioning whether the framework should address gender at all.

Led by Washington, opposing delegations argued that UN environmental bodies must restrict their mandates to basic biological definitions. The US delegates reiterated a sweeping stance to eliminate gender terminology across international environmental agreements. Washington demanded replacing gender references with binary biological sex categories, refusing to join consensus on the proposed gender action plan.

“It is the current policy of the United States to remove gender language from United Nations documents,” the American delegate stated, urging the conference to drop the plan.

Argentina, Russia, and Saudi Arabia joined Washington to form a unified blockade, attacking the plan’s ideology, expanded scope, and administrative burdens. By withholding consensus and rejecting a formal contact group, the coalition stalled the decision and forced informal talks behind closed doors.

Health advocates defend gender-responsive safety

Speaking for Pacific small island developing states, Fiji’s delegate (right) warns Geneva negotiators that gender-blind chemical indicators leave critical exposure pathways invisible.
Speaking for Pacific small island developing states, Fiji’s delegate (right) warns Geneva negotiators that gender-blind chemical indicators leave critical exposure pathways invisible.

Public health advocates and trade union federations vigorously defended the plan in plenary, arguing chemical threats cannot be detached from workplace realities. They stressed that physical susceptibility and gendered divisions of labour combine to dictate everyday toxic exposure.

“A gender-responsive occupational health and safety approach makes the workplace safe for everybody,” the International Union of Food and Allied Workers declared. Unions warned that an international chemical framework that ignores gender realities is doomed to fail.

Small island developing states pointed out that women in the Global South face extreme, unmonitored chemical hazards. Delegations emphasised that informal waste recyclers and rural agricultural workers routinely handle toxic substances without protective gear.

Speaking for Pacific small island developing states, the Fijian delegate warned that without sex-disaggregated biological monitoring, critical exposure pathways remain invisible to regulators. “A gender-blind indicator measures only half of reality,” she added.

Mexico, Canada, the European Union, and the United Kingdom strongly supported adopting the plan without delay. They argued that mainstreaming gender perspectives strengthens chemical governance and ensures equitable protection across all communities.

Procedural scramble before Friday deadline

Geneva’s International Conference Centre hosts the first Global Framework on Chemicals summit, where negotiations stalled over a proposed Gender Action Plan.
Geneva’s International Conference Centre hosts the first Global Framework on Chemicals summit, where negotiations stalled over a proposed Gender Action Plan.

Faced with unyielding opposition from four influential capitals, acting conference president Magdalena Frydrych was forced to abandon plans for a formal contact group. These groups require formal mandates and plenary reporting, which the blocking coalition refused to endorse.

Instead, the presidency proposed an ad-hoc informal group behind closed doors. An immediate scramble followed: 24 delegations hit their microphone buttons to demand a seat at the table.

The informal group faces a race against the clock to draft acceptable language before final resolutions are gavelled on Friday. Negotiators must determine whether the gender plan survives as an operational policy or gets stripped of actionable accountability.

The stand-off exposes a stark divide between cutting-edge exposure science and multilateral diplomacy. While UN scientists warned this week of pervasive generational damage across human biology and called for sex- and gender-differentiated monitoring, opposing capitals refused to even allow gender terminology in conference resolutions.

See related story:

Delegates Clash Over Hazardous Pesticide Metrics at UN Chemicals Summit

Image Credits: MART PRODUCTION/Pexels, WHO, Felix Sassmannshausen/HPW, EqualStock, Felix Sassmannshausen.

Spanish Health Minister Dr Mónica García Gómez

The Spanish government and 20 other countries have committed to reducing their national obesity rates by 5% by 2030 as part of a global call to action against obesity launched on Tuesday with the World Health Organisation  (WHO and UNICEF.

“More than one billion people now live with obesity, and there are now more school-age children with obesity than children who are underweight,” said WHO Director-General Dr Tedros Adhanom Ghebreyesus at a media briefing on Tuesday.

“If obesity were a virus, it would be called a pandemic, and the world would be racing to stop it,” Tedros added.

“The call to action asks countries to respond with that same urgency. It commits countries to one strategy with three tiers. The first tier is prevention for the whole population, including taxes on sugary drinks, clear food labels, limits on marketing unhealthy food to children, and healthy food in schools. 

“The second tier is early action for people at higher risk before risk becomes disease, and the third tier is care for everyone living with obesity, including access to effective treatment without stigma.”

Spanish Health Minister Dr Mónica García Gómez said that countries “know what works”. 

“We have the evidence, we have the tools, and we have the ability to make a real difference. So now let’s make it happen,” she told the briefing. 

Spain has brought together 18 government ministers to implement its national plan to reduce childhood obesity, she said.

“Children don’t live their lives in separate ministries, so we shouldn’t design our policies as if they did,” she said.

“Childhood obesity is about much more than individual choices. It is about the condition in which children grow up. It is about whether families can afford healthy food, whether children have safe places to play, whether their neighbourhoods encourage physical activity, and whether every child has the same opportunities to grow up healthy.”

‘Complex disease’

Obesity is a form of malnutrition and a chronic, complex disease that increases the risk of several noncommunicable diseases, including cardiovascular diseases, diabetes and some cancers, according to WHO.

Prevalence has more than doubled among adults and quadrupled among adolescents since 1990. In 2025, obesity overtook underweight as the most common form of malnutrition among children and adolescents aged 5–19 years.

“Obesity is one of the defining public health challenges of our time, but its continued rise is not inevitable,” said Tedros. “I commend the commitment shown today by governments to turn the tide on obesity by creating healthier environments, protecting children and ensuring everyone living with obesity can access the care and support they need.”

Welcoming the call, the World Obesity Federation said that, for the first time, governments have committed together to “preventing obesity across the population, acting early for people at higher risk, and providing stigma-free care for everyone living with obesity”. 

Bahrain, Barbados, Botswana, Brazil, Brunei Darussalam, Egypt, Eswatini, Ireland, Jordan, Malaysia, Mauritius, Mexico, Panama, the Philippines, Portugal, Seychelles, Slovenia, South Africa, Thailand and Uruguay are part of the call. 

These countries are part of the WHO acceleration plan to stop obesity adopted by the World Health Assembly in 2022.

WHO logo on the exterior of WHO headquarters premises in Geneva, Switzerland on 19 July 2023.

The election to lead the World Health Organization (WHO) offers an opportunity to rethink not simply who should lead the institution, but how it should exercise leadership in a world that has changed profoundly. The greatest challenge facing the next Director-General may be transforming an organization whose political masters are reluctant to change.

When the seven candidates for WHO Director-General meet Member States in Geneva on 18–19 November 2026, they will be asked what they would change. Governments should face a question of their own: what changes are they prepared to authorize, finance and defend? The next Director-General can set priorities and propose reforms. Whether those reforms take hold will depend on decisions that only Member States can make.

The wrong starting question

As the contest for the next Director-General of the World Health Organization (WHO) gathers momentum, candidates are presenting competing visions of their leadership role on WHO’s future. But what if the debate so far has focused on the wrong question?

The most consequential decision facing member states may not be whom to elect, but whether they are prepared to change the institutional model that the successful candidate will inherit.

Having spent almost three decades working within the United Nations system, the WHO and its governance bodies, we have witnessed successive efforts to reform international institutions. One recurring lesson is that organizations often change their structures more readily than they change their strategic direction. They become more efficient at doing what they have always done, without necessarily asking whether those are still the right things to do.

WHO now confronts precisely this dilemma.

Its ongoing financial crisis has generated an understandable focus on budgets, staffing and organizational restructuring. Yet the deeper challenge may be that over the last few decades, global health architecture has evolved faster than WHO’s institutional model.

The next Director-General could be the most capable manager WHO has ever had and still fail to transform the organization. The forthcoming election should therefore become something more ambitious than a contest between individuals. It should become a constitutional moment for WHO – not necessarily to rewrite its Constitution, but to rethink how its constitutional mandate can be fulfilled in a fundamentally different world.

Three challenges, one institutional mismatch

The United States' withdrawal from the WHO left the organisation with a huge funding gap.
The United States’ withdrawal from the WHO left the organisation with a huge funding gap.

WHO’s predicament is commonly described in terms of three challenges: an expanding technical agenda, financial vulnerability and geopolitical fragmentation.

The scale of the unfinished health agenda is striking. The WHO–World Bank 2025 Global Monitoring Report on universal health coverage estimates that 4.6 billion people were not fully covered by essential health services in 2023, while 2.1 billion experienced financial hardship from out-of-pocket health expenditure in 2022. Meanwhile, pandemics, noncommunicable diseases, emerging infections, antimicrobial resistance, climate change and artificial intelligence continue to reshape global health priorities.

WHO carries broad responsibility for global health leadership and is expected to address virtually every dimension of health and its determinants. Yet it does not control many of the instruments through which that leadership must be exercised. 

The financial crisis has exposed a longstanding structural weakness in WHO’s financing model, although important progress has been made. Member states approved successive 20% increases in assessed contributions for 2024–2025 and 2026–2027 – a cumulative increase of 44% over two biennia. This represents a significant commitment to more sustainable financing, with the longer-term objective of assessed contributions covering 50% of WHO’s core budget by 2030–2031.

Yet financial vulnerability persists, sharpened by the exit of the United States, previously WHO’s top donor, which it declared complete in January 2026, and by Argentina’s notification of withdrawal. 

WHO’s proposed base programme budget for 2026–2027 was reduced by more than one-fifth, from $5.3 billion to $4.2 billion. Perhaps more revealing is that WHO ended the 2024–2025 biennium with 96% of its base programme budget financed, but only 85% implemented. This exposes a paradox: an organization can appear almost fully financed while lacking the ability to achieve its collectively agreed priorities.

Geopolitical fragmentation compounds the other two. Global health is increasingly shaped by intensifying competition, multipolarity and declining trust in international institutions. Consequently, Member States have different expectations of WHO and its reform, different approaches to global health cooperation and sometimes conflicting views on the balance between national sovereignty and collective action.

These challenges are real. But they also reveal a deeper responsibility: authority mismatch.

WHO is expected to exercise leadership over a global health system in which authority, financing and implementation are increasingly distributed across institutions that it does not control.

The result is an institution expected to lead comprehensively, financed selectively and increasingly required to negotiate its influence across a fragmented system by maintaining its scientific credibility and political legitimacy.

 The task for the global community is not simply how to sustain WHO as it exists today. It is whether the institutional model we are supporting is sufficiently adapted to the world in which WHO must operate tomorrow.

WHO’s greatest risk may not be decline, but irrelevance

WHO is unlikely to disappear. Its constitutional mandate, global membership, scientific authority and historical legitimacy provide strong foundations for institutional survival. But survival is not the same as relevance.

An organization can stabilize its finances, maintain its global presence, publish authoritative guidance and continue convening international meetings while gradually losing influence over the decisions that matter most.

Consider where some of the most consequential decisions about global health are increasingly being made.

Development banks determine major health investments. Global health initiatives allocate substantial programme resources. Governments and private companies shape technological innovation. Pharmaceutical companies influence access to medical products and their research and development. Regional institutions are developing their own approaches to health security and cooperation.

WHO remains involved in many of these discussions. But involvement is not necessarily leadership. The uncomfortable question is whether WHO’s influence over these decisions is keeping pace with its responsibility for their consequences. The danger is not that WHO disappears. It is that the world gradually learns to operate around it.

This possibility should fundamentally change the way we assess WHO reform. Success cannot be measured simply through institutional survival, financial stability or organizational efficiency. It must be measured by whether WHO continues to shape the decisions that determine the health of populations.

A WHO that survives but becomes increasingly peripheral to those decisions would represent a failure of reform, however successful its internal restructuring might appear.

The World Bank and other development banks determine major health investment – not WHO.

Three reforms, but only one future

What makes the present moment particularly significant is the convergence of three reform processes: WHO’s internal reform, WHA79 global health architecture reform process and the wider UN80 Initiative.

Each addresses a different problem, but together they could reshape WHO’s institutional future.

WHO could reduce the technical capacities that a reformed global health architecture subsequently requires. UN consolidation could weaken specialized functions essential to WHO’s authority. Global health architecture reform could generate new coordination mechanisms without resolving the institutional competition and fragmented financing that make coordination necessary.

The opportunity is to connect these processes into a coherent vision of WHO’s future and to mitigate the risk that three separate reform agendas produce three different answers to the same institutional question.

But there is an even more fundamental issue: what kind of influence should WHO seek to exercise in the emerging global health system?

More power without more institutional territory

The conventional response to institutional vulnerability is to protect mandates, mobilize additional resources and preserve operational capacity. But perhaps WHO’s future strength requires a different understanding of institutional power. There is a distinction between the power to deliver and the power to shape what others deliver.

WHO will never command the combined financial resources of development banks, governments and global health initiatives. Nor should it attempt to replicate their operational capacities. Its unique opportunity lies in influencing how those resources are used, which scientific standards guide their application, and whether their collective contribution advances global health priorities.

Envisage a WHO whose technical recommendations are systematically reflected in major health investments; whose scientific standards inform procurement and implementation across global health institutions; and whose assessment of emerging health risks influences decisions well beyond its own programmes.

Such an organization could exercise greater influence without necessarily managing a larger operational portfolio. This would represent a shift from institutional centrality to system leadership.

The distinction is especially important for WHO’s normative work. A global clinical guideline may be scientifically impeccable, but its impact depends on whether countries can adapt it, finance its implementation and incorporate it into clinical practice.

WHO’s responsibility should not end when the guideline is published. Nor does WHO need to undertake every activity necessary for its implementation. Its leadership should be judged by whether it can mobilize the wider system to make authoritative knowledge consequential.

Consider the implications for artificial intelligence. WHO may never possess the technological resources of major private companies. But it could shape the standards governing the use of AI in health, ensuring that scientific integrity, patient safety and equity are not subordinated to commercial or technological priorities.

The same principle applies to pandemic preparedness, antimicrobial resistance and universal health coverage.

WHO should not seek to become the largest actor in every area of global health. It should become the actor whose contribution makes the collective efforts of others more effective. That is a different model of institutional power – and potentially a more sustainable one.

The courage to relinquish

The WHO issued a new directive introducing leave for campaigning Regional Directors for the first time.
The next WHO leadership may require something more difficult: the willingness to relinquish selected institutional responsibilities to strengthen WHO’s wider influence.

The next Director-General will undoubtedly be expected to defend WHO’s interests. But transformational leadership may require something more difficult: the willingness to relinquish selected institutional responsibilities to strengthen WHO’s wider influence. This is an uncomfortable proposition for any international organization.

Institutional leaders are generally rewarded for securing resources, expanding programmes and protecting organizational territory. Success is rarely associated with deciding that another institution should undertake a function previously performed by their own. Yet a more coherent global health architecture cannot emerge if every institution enters the reform process determined to preserve its existing responsibilities.

WHO cannot credibly lead system-wide reform while treating its own institutional arrangements as exempt from reconsideration. This does not mean weakening WHO’s scientific authority, abandoning its country presence or relinquishing indispensable emergency functions. On the contrary, these capabilities must be protected. Nor should the transfer of responsibilities become an excuse for donors to withdraw resources or for countries with limited institutional capacity to receive less support. It means recognizing that leadership and ownership are not synonymous.

In selected areas, WHO may need to do less directly to achieve more collectively. In others, particularly where countries lack alternative technical or operational capacity, it may need to do more. The strategic question is not how much WHO should retain, but which distribution of responsibilities produces the greatest benefit for countries.

This should become a defining test of the candidates.

What would they be prepared to relinquish?

What would they protect, even under severe financial pressure?

And where would they seek to expand WHO’s influence without expanding its bureaucracy?

The answers would reveal far more about their understanding of transformational leadership than familiar commitments to efficiency, innovation and partnerships.

An election that challenges the electorate

The 79th World Health Assembly: We should ask not only what candidates are promising member states, but what member states are prepared to promise the successful candidate.

There is a paradox at the heart of the forthcoming election. Member states are seeking a leader capable of transforming WHO. Yet those same member states determine the organization’s mandate, leadership and hierarchy, approve its budget, influence its financing and govern many of the other institutions with which WHO must cooperate. 

The next Director-General will be asked to make difficult choices within a system that governments themselves have created. 

Can the WHO Secretariat be expected to prioritize effectively when its governing bodies continue to add responsibilities without necessarily providing corresponding resources? Can it exercise independent scientific leadership when political considerations influence the reception of its recommendations? Can it achieve greater coherence, efficiency and accountability without addressing the long outstanding hierarchical, governance and management challenges across its headquarters, regional and country levels? Can it lead a better coordinated global health architecture when governments pursue different institutional interests across the organizations they govern?

These are not questions that even the most capable Director-General can answer alone.

The election should therefore produce something more than a new leader and a new strategic vision. It should establish a Transformation Compact between the incoming Director-General and Member States. Its central principle would be simple: the Director-General commits to making difficult institutional choices; member states commit to creating the political, governance and financial conditions that make those choices possible.

This would mean accepting that some existing activities may need to end, that collectively agreed priorities require predictable and sufficiently flexible financing, and that scientific authority must be protected even when its conclusions are politically inconvenient.

It would also mean supporting a clearer distribution of responsibilities across global health institutions rather than expecting WHO to resolve fragmentation through coordination alone. The compact should not become another elaborate reform instrument. Its value would lie in making explicit the reciprocal obligations that are too often absent from leadership elections. 

The Eightieth World Health Assembly (WHA80) in May 2027 offers a practical opportunity to establish such a compact, linking the appointment of the next Director-General with the decisions emerging from global health architecture reform. We should ask not only what candidates are promising member states, but what member states are prepared to promise the successful candidate.

The real choice before WHA80

WHO’s defining moment is not simply the financial crisis, the reform of the global health architecture or the election of its next Director-General. It is their convergence, alongside the wider transformation of the United Nations.

WHO could emerge from this period as a smaller institution that continues to operate according to essentially the same institutional logic. Or it could emerge as an organization whose influence extends far beyond its own operational footprint. The choice is not necessarily between a larger and a smaller WHO. It is between preserving an institution, revisiting its role and renewing its leadership. The world does not need WHO to do everything. It needs WHO to do what only WHO can do—and to make possible what no institution can achieve alone.

The next Director-General must have the conviction to challenge established institutional practices and programmes, reconsider traditional boundaries and articulate a compelling vision of WHO’s future. 

But that is only half the leadership challenge.

The other half lies with the governments that will elect that person and will take decisions that change what WHO does, provide the resources to carry them out, and stand behind those decisions when they become politically difficult. 

The defining choice of the 2027 election is not simply whether the next Director-General will have the courage to transform WHO. It is whether Member States will have the courage to transform the conditions under which WHO must lead. Without that commitment, the world may elect a transformational leader only to condemn her or him to managing the crisis. 

 

Dr Mubashar Sheikh is a former WHO Director of Quality Assurance, Norms and Standards. He was earlier Executive Director of the Global Health Workforce Alliance, WHO Representative in Iran and UN Resident Coordinator in Kuwait.

Dr Ren Minghui is a professor at the Institute for Global Health and Development, Peking University. He is a former WHO Assistant Director-General and previously headed international cooperation at China’s national health ministry.

 

Image Credits: WHO, Anonymous/HPW, X/Tedros Adhanom Ghebreyesus, WHO/Antoine Tardy .

WHO Director-General candidate panel (left to right): María Neira, Gevorg Tamamyan, Hanan Al-Kuwari, and Budi Gunadi Sadikin address the World Health Summit in Berlin.
WHO Director-General candidate panel (left to right): María Neira, Gevorg Tamamyan, Hanan Al-Kuwari, and Budi Gunadi Sadikin address the World Health Summit in Berlin.

Children with cancer in wealthy countries have survival rates of around 85 percent, while in parts of Africa, survival can fall to 20 percent or 30 percent, and sometimes even lower. For Dr. Gevorg Tamamyan, an Armenian paediatric oncologist seeking to become the next director-general of the World Health Organization (WHO), the disparity illustrates one of the biggest failures of global health.

“People are dying not because of the lack of knowledge or science, but because of lack of equity, lack of access,” Tamamyan said.

Speaking on the Inside Geneva podcast, produced in partnership with the Geneva Graduate Institute’s Global Health Centre and SWI swissinfo, Tamamyan outlined his ambition to reform WHO, arguing that the organisation must become more responsive to the needs of countries and communities.

Unlike many candidates, Tamamyan comes from outside WHO and was nominated by Botswana rather than his native Armenia.

His experience treating children with cancer has shaped his approach to global health. He pointed to Armenia, where paediatric cancer survival has risen from approximately 0 percent to 5 percent in the 1990s to more than 75 percent, as evidence that improving access and strengthening local capacity can transform outcomes.

Tamamyan also questioned the pace of international health decision-making, arguing that countries cannot afford to wait years for meetings, recommendations and implementation.

“How long it takes to get these meetings? How long it takes to get these recommendations? How long it takes to implement all this? It’s years. And it’s horrible,” he said.

He called for WHO to shift its focus toward stronger country-level operations rather than concentrating authority in Geneva.

“The strongest foundation of WHO should be in the countries,” Tamamyan said.

Despite the organization’s shortcomings, he defended its importance at a time of declining international funding and growing challenges to global health cooperation.

“I’m convinced that the world is much better with World Health Organization than without it,” he said.

Listen to the full podcast:

The interview series with WHO DG candidates is being co-produced by the SwissInfo media platform with the Geneva Graduate Institute’s Global Health Centre, as part of a media collaboration on the upcoming WHO election  also supported by Health Policy Watch.

See more about the candidates on Health Policy Watch’s special WHO election website.

Image Credits: Elaine Ruth Fletcher/HPW.

Delegates gather in Geneva as the UN Global Framework on Chemicals opens amid clashes over binding pesticide phase-out metrics.
Delegates gather in Geneva as the UN Global Framework on Chemicals opens amid clashes over binding pesticide phase-out metrics.

African nations and health advocates clashed with agrochemical manufacturers at the opening of the UN Global Framework on Chemicals conference in Geneva on Monday over whether pesticide phase-outs will be strictly measured or left to voluntary pledges. Meanwhile, medical networks urged negotiators to place human health – and toxic-free healthcare supply chains – at the centre of global chemical management.

Toxic agricultural chemicals cause over 400 million acute poisonings every year, sickening nearly half the world’s farmers and agricultural workers. Yet as the first international conference of the United Nations Global Framework on Chemicals opened in Geneva on Monday, governments arrived with no agreed system to track whether the world is actually phasing them out.

The week-long summit brings together delegates from over 150 governments alongside chemical manufacturers, health agencies, trade unions, and civil society groups from 16 to 20 November. Meeting at the Geneva International Conference Centre, negotiators are tasked with turning 28 voluntary targets adopted in Bonn, Germany, in 2023 into concrete, measurable actions across global industrial and agricultural supply chains.

The pesticide tracking gap triggered an immediate clash between African delegations demanding concrete tracking metrics and chemical manufacturers lobbying to rely on voluntary industry standards. The dispute centres on Target A7, an international commitment to phase out highly hazardous pesticides in agriculture by 2035 where risks are unmanaged and safer alternatives exist.

Because the framework is a voluntary, non-binding instrument, agreed indicators represent the only formal accountability mechanism governments have to verify whether targets are met. While technical working groups approved consensus metrics for foundational capacities – such as establishing national poison centres – negotiators arrived in Switzerland without agreement on a single metric to track pesticide phase-outs.

African Group pushes strict pesticide metrics

A delegate from The Gambia speaks on behalf of African nations demanding strict pesticide phase-out metrics at the Geneva chemicals summit.
A delegate from The Gambia speaks on behalf of African nations demanding strict pesticide phase-out metrics at the Geneva chemicals summit.

Faced with an unmeasured target, The Gambia introduced a formal proposal on behalf of the 54 African Group nations. The submission demands concrete phase-out benchmarks to evaluate real-world hazard reduction.

“For the African region, implementation must translate into real actions on issues that place our people and environment at risk,” said the delegate from The Gambia. The African proposal requires governments to document legal bans, track import prohibitions, and verify domestic pesticide phase-outs.

The European Union and host nation Switzerland broadly supported establishing robust monitoring mechanisms. They emphasized that clear indicators are essential to guide international technical assistance and financial allocations.

However, European and Swiss delegates urged a pragmatic, phased approach to prevent procedural gridlock. They argued that disputed agricultural indicators should be referred to intersessional working groups rather than delaying the immediate adoption of mature metrics.

Exporters warn of disguised trade barriers

Spraying pesticides on a quinoa crop in Bolivia. Major agricultural exporters warn binding UN metrics could disrupt global food trade.
Spraying pesticides on a quinoa crop in Bolivia. Major agricultural exporters warn binding UN metrics could disrupt global food trade.

Major agricultural exporting countries and chemical manufacturing states moved quickly on Monday to reject mandatory global tracking metrics for hazardous pesticides. Representing an agricultural economy feeding 600 million people, Argentina cautioned that rigid international rules must not evolve into disguised trade barriers.

Delegations including Chile and Brazil stressed that hazard assessments cannot replace local risk evaluations. Meanwhile, Saudi Arabia fought to shield confidential business data and proprietary chemical formulations.

Developing nations including Algeria and Iran cautioned that enforcing complex supply-chain tracking would create disproportionate administrative burdens. Delegations such as Syria warned that poorer countries lack specialised laboratories to independently verify imported active ingredients entering their borders.

Without financial assistance and technology transfer, delegates stressed that small customs authorities cannot enforce international chemical prohibitions. They insisted that global reporting mandates must match national implementation capacities.

Industry defends voluntary pledges

A CropLife International delegate addresses Geneva talks on tracking progress, defending voluntary corporate stewardship over mandatory global pesticide phase-out metrics.
A CropLife International delegate addresses Geneva talks on tracking progress, defending voluntary corporate stewardship over mandatory global pesticide phase-out metrics.

Standing in direct opposition to the African proposal, CropLife International, representing agrochemical giants including Bayer, Syngenta, and BASF, submitted counter-proposals anchored in voluntary corporate stewardship. The trade association argued that rigid global tracking metrics would stifle agricultural innovation and restrict essential pest-management tools used by smallholder farmers.

“[Indicators must remain] practical and implementable, and not unnecessarily burdensome, while building on existing regulatory and policy frameworks,” said CropLife International on Monday afternoon. Industry representatives insisted that global tracking should draw strictly from established voluntary mechanisms overseen by the Food and Agriculture Organization and World Health Organization (WHO).

Manufacturers maintained that responsible use training and voluntary recycling and disposal programmes deliver faster safety improvements than international reporting requirements. They urged delegates to focus on strengthening national pesticide registration capacities rather than imposing top-down tracking metrics across global supply chains.

Severe gaps in frontline poison surveillance

The World Health Organization warns Geneva chemical talks that missing poison control centres leave millions of acute pesticide poisonings unrecorded.
The World Health Organization warns Geneva chemical talks that missing poison control centres leave millions of acute pesticide poisonings unrecorded.

The debate over agricultural metrics unfolds against a backdrop of severely fractured clinical surveillance systems across low- and middle-income nations. More than half of all countries worldwide still lack a functioning poison control centre, the WHO reported on Monday.

“Major challenges remain, including fragmented data, weak institutional linkages, and the absence of poison centres in more than half of countries,” the agency warned. That infrastructure deficit leaves rural hospitals and frontline doctors poorly equipped to diagnose or treat acute toxic exposures in agricultural communities.

Without specialised clinical toxicology networks, millions of pesticide-induced acute poisonings and chronic chemical-related illnesses go unrecorded in official health registries every single year.

Civil society advocates demanded formal mechanisms to integrate community-generated evidence, ensuring that rural pesticide poisonings are reflected in official United Nations monitoring. They argued that waiting for underfunded national bureaucracies to compile hospital registries ignores the severe health burdens borne by agricultural labourers.

On the plenary floor, the International Pollutants Elimination Network (IPEN) called for “strengthening the recognition of community-generated evidence by recommending mechanisms for inclusion in official GFC monitoring and reporting.” Civil society advocates argued this is vital to expose true poisoning rates where state health infrastructure cannot reach.

Putting health at the centre of chemical management

Alessandra Azevedo of Projeto Hospitais Saudáveis argues in Geneva that protecting human health must be the focus of chemical management.
Alessandra Azevedo of Projeto Hospitais Saudáveis argues in Geneva that protecting human health must be the focus of chemical management.

Public health advocates insisted that protecting human well-being must stand at the absolute centre of international chemical management. Addressing delegates in Geneva, Alessandra Azevedo of Projeto Hospitais Saudáveis declared that people and the planet must anchor every sectoral implementation strategy.

Representing the healthcare industry programme co-convened with the WHO, Azevedo warned that toxic substances permeate modern clinical supply chains. She argued that major hospitals must leverage their immense institutional purchasing power to eliminate hazardous phthalates, toxic plastics, and harmful medical disinfectants.

“Indicators must not merely count activities, but focus on the prevention of harm and reduced chemical use,” Azevedo told Health Policy Watch. She stressed that established clinical standards applied across 80 countries could serve as ready-made metrics to track toxic chemical reductions in healthcare.

Civil society health groups reinforced this call, reminding delegates that delayed regulatory decisions translate directly into preventable disease and occupational fatalities. Meanwhile, the International Trade Union Confederation reminded delegates that toxic exposures kill over one million workers annually, demanding guaranteed rights to know.

Washington and chemical manufacturers challenge regulations

Speaking at the Geneva chemicals summit, a United States representative opposes generic hazard assessments that exclude country-specific exposure data.
Speaking at the Geneva chemicals summit, a United States representative opposes generic hazard assessments that exclude country-specific exposure data.

Tensions widened on Monday afternoon from farm chemicals to broad national legislation, as delegates debated United Nations guidelines designed to help developing nations rapidly ban hazardous industrial substances. The United States criticised draft United Nations guidance intended to help resource-constrained governments rapidly adopt prohibitions already enacted by advanced regulatory agencies.

“We do not agree with the proposed approaches on the use of generic risk assessments that do not incorporate country-specific exposure information,” the United States representative told delegates.

Washington also strongly warned against “over-reliance on designations of chemicals of concern made by other jurisdictions, nor the implementation of arbitrary bans based on foreign regulatory decisions.”

Industry groups such as the International Council of Chemical Associations along with Saudi Arabia immediately endorsed the American position, urging negotiators to overhaul the United Nations guidance document. Chemical manufacturers argued that regulatory models should prioritise voluntary capacity building and commercial confidentiality rather than facilitating top-down chemical prohibitions.

Meanwhile, public health advocates warned that forcing poor countries to duplicate complex risk evaluations effectively prevents them from restricting hazardous imported substances. They argued that developing nations lack the toxicological laboratories required to conduct domestic assessments, leaving populations exposed to dangerous foreign chemicals.

Late-night negotiations to break metric deadlock

The Geneva International Conference Centre hosts the first UN Global Framework on Chemicals summit amid clashes over binding pesticide metrics.
The Geneva International Conference Centre hosts the first UN Global Framework on Chemicals summit.

To resolve the impasse, the plenary formally established the Contact Group on Tracking Progress, co-chaired by Antigua and Barbuda and Czechia. The working group has been tasked with drafting compromise text that bridges CropLife’s voluntary stewardship proposals with the African Group’s phase-out metrics.

Delegates must also determine whether unresolved targets will be deferred to an intersessional working group ahead of the second international conference in 2029. With evening negotiating sessions now underway, the conference faces a tightly compressed timeline to deliver an agreed, credible global monitoring architecture.

A stocktaking plenary on Wednesday morning will evaluate whether contact groups have achieved consensus on pesticide metrics, confidentiality rules, and national reporting duties. Negotiators must decide whether to adopt concrete tracking indicators or settle for voluntary corporate pledges before final resolutions are gavelled on Friday.

See related story:

Toxic Chemicals Abundant in Cosmetics, Hair Products, with Little Regulation

Image Credits: Michael Hermann/Wikimedia, Felix Sassmannshausen/HPW, Felix Sassmannshausen.

At the Malbrán Institute in Buenos Aires, Argentina, scientists study bacteria samples from across Latin America to track and control the emergence of antimicrobial resistance (AMR).

Drug-resistant bacterial infections could cause up to 39 million deaths by 2050 without urgent action, according to the latest assessment released by the World Health Organization (WHO) on Monday.

Globally, 183 countries have a plan in place to tackle antimicrobial resistance (AMR), but only 42 countries have financed their plans. The data is from the Tracking Antimicrobial Resistance Country Self-assessment Survey (TrACSS) that countries took.

“Bacterial antimicrobial resistance was estimated to be directly responsible for over one million deaths in 2021, and it was associated with about 4.7 million deaths. And those are the statistics of 2021,” said Dr Jean Pierre Nyemazi, acting director of the WHO’s AMR department.

“At the same time, the pipeline for new treatments is not keeping pace with rising resistance; as more bacteria become resistant to existing antibiotics, we are running out of effective treatment options,” he explained.

This makes treating routine infections more expensive, longer and is toxic for the patient’s body.

A decade of AMR plans

Most countries now have an AMR plan in place, but few have allocated finance for these plans.

For 10 years now, countries have been implementing their national AMR action plans. About 183 of 194 countries responded to the survey in 2026. While nearly every country has an AMR plan now, only 42 (22%) of the countries have funded their plans.

“Tracks matters at two levels. At the national level, completing the survey brings ministries and sectors around a table to take stock, see where the gaps are, and then decide where to focus next,” said Pravarsha Prakash, technical officer of AMR monitoring and evaluation, WHO. 

“At the global level, it’s how we track progress on national action plans and towards the targets countries agreed at the UN General Assembly in 2024,” she explained. 

Apart from the indiscriminate use of antibiotics, limited access to clean water and sanitation facilities worsens AMR.

Laboratory testing still falling short

Capacity to test for AMR in fungal infections is currently lagging.

AMR occurs when bacteria, viruses, fungi and parasites do not respond to antimicrobial medicines and become nearly impossible to treat. 

Countries have limited capacity to test for AMR as well. While 131 (72%) of the countries have the capacity to test for selected bacteria, only 72 (39%) can test for selected fungi. This is half of the target for 2030.

The target is for 80% of countries to be able to test for resistance in all bacterial and fungal pathogens monitored by WHO.

Fungal infections

While bacterial and viral infections do get attention, fungal infections do not get as much attention.

“Even in their best-equipped laboratory, typically located in the capital city, more than one in four countries cannot test for resistance in the bacteria monitored. And for fungi, the gap is even wider,” said Dr Silvia Bertagnolio, unit head, AMR surveillance and laboratory strengthening. 

WHO is now also providing countries the AMR Diagnostic Initiative, with a prioritized list of the diagnostic tests needed to detect bacterial and fungal infections and AMR. 

More countries are tracking antibiotic use 

There is growing awareness of antibiotic resistance.

A key takeaway from the survey is that more countries are tracking the use of antibiotics. Nearly 113 countries monitor the use nationally and 109 countries have standardized systems for AMR surveillance in place.

However, while hospitals have been given guidelines to limit the use of antibiotics, there is little room for feedback.  

The response to tackling AMR is investing in the social determinants of health, WHO experts said.

“We have evidence that show that investments in infection prevention and control, vaccination, water sanitation, hygiene, responsible antimicrobial use, and research and development of new medicines through the One Health approach can save lives and generate enormous economic returns,” said Nyemazi of the AMR department.

WHO is set to mark the World AMR Awareness Week 2026 from 18 November.

Image Credits: WHO/Sarah Pabst, WHO.

Democratic Republic of Congo (DRC) President Félix Tshisekedi (left) with DRC national Dr Jean Kaseya, shortly after being appointed  Director-General of the Africa CDC.

Dr Jean Kaseya is campaigning to be reappointed as Director-General of the Africa Centres for Disease Control and Prevention (CDC) – amid serious allegations of threats to diplomats, staff intimidation, lavish spending and a shrinking budget.

Eight highly placed sources, mostly CDC staff or former staff, told Health Policy Watch that Kaseya has threatened two very high-profile AU female diplomats; removed and reassigned staff who question his decisions; and appointed staff without following proper procedures. 

Four other staff or former staff spoke through intermediaries or shared written documentation. All spoke on condition of anonymity for fear of reprisals. 

In addition, the financial management letter for 2025, issued by the African Union’s Board of External Auditors and seen by Health Policy Watch, flags 49 flaws in the year’s financial management processes. 

The letter does not give the overall budget for the year 2025 but cites a cash balance of just $52.9 million at the end of 2025, while Africa CDC’s Annual Report for 2025 said it was managing a “grant portfolio” of $463 million.  

Automatic re-appointment?

Kaseya’s term ends in February, and he could be reappointed for another four years if the Africa CDC governing board recommends this to African Union (AU) Heads of State, and the AU Assembly accepts this.

However, a brand-new group of eight AU member states, represented by their health ministers, has just joined the CDC governing board as part of the periodic shuffle of membership. 

The new members, who attended an orientation meeting on 10 November, are from  Cameroon, Gabon, Gambia, Kenya, Namibia, Sierra Leone, Uganda and Zimbabwe. (North Africa has not yet nominated its two representatives.)

The governing board is due to discuss Kaseya’s reappointment at its first official meeting on 22 November – apparently based on an April assessment conducted by the AU Commission Chairperson. Outside observers expect the process to be a virtual rubber-stamp.

“The governing board of Africa CDC can do an evaluation of the DG. And, if all agree, they can recommend to the [AU] Committee of Heads of State to reappoint him,” Dr Claudes Kamenga, Kaseya’s Chief of Staff, told Health Policy Watch.

Staff petition against reappointment

The Africa CDC headquarters in Addis Ababa, Ethiopia.

A petition from “concerned senior staff” circulated last week urges the governing board and the AU Permanent Representatives Committee (PRC) not to reappoint Kaseya. Health Policy Watch received the petition from several credible sources who vouch for its authenticity.

The petition claims that a performance appraisal of Kaseya completed in April has legal and procedural problems, and should not be the basis for his reappointment.

The appraisal, signed by AU Commission (AUC) Chairperson Mahmoud Ali Youssouf, covers Kaseya’s entire period of office (2023-2026), although Youssouf only took office in March 2025. It was also completed before the current Ebola outbreak, one of the biggest challenges of Kaseya’s term so far.

The petition-writers say that they have “direct knowledge of Africa CDC’s operations, management and regulatory framework”. They defended their anonymity, citing fears of “retaliation and victimisation”, noting that their action is within the parameters of AU whistleblower regulations. 

Lingering questions remain about Kaseya’s initial appointment almost four years ago. He was not the highest-ranked candidate – former Guinea-Bissau Health Minister Dr Magda Robalo was, and she questioned why she was overlooked. 

At the time, Rwandan President Paul Kagame wrote that “no debate was allowed” on Kaseya’s appointment and that it was the only agenda item on which discussion was “forbidden”, according to a letter he sent to the AU Commission Chairperson in March 2023.

In its written response to Health Policy Watch, Africa CDC referred to sections of the Africa CDC Statute which set out that the DG undergoes a “selection and appointment process”, not election.

Alleged threats to female diplomats

Three highly placed sources told Health Policy Watch that Kaseya threatened two very senior female AU Commission diplomats in front of several witnesses. Security personnel intervened in at least one of these incidents, the sources said.

Health Policy Watch knows the identities of both diplomats and reached out to them for comment but did not get a response at the time of publication.

The sources also said Kaseya was told to take leave after the second incident. However, the staff petition claims he was suspended for 10 days after “inappropriate conduct” towards an “AUC official”, and asks why this was not noted in his appraisal.

While Africa CDC did not respond to Health Policy Watch questions about whether Kaseya has threatened any female diplomats, it stressed that he “has never been suspended, sanctioned or placed on administrative leave since taking office in April 2023”. 

“The Director General, as an elected official, cannot be suspended or asked to take leave (by whom?)  without a proper procedure that is written, with accusations formally formulated and known to the AU policy organs,” noted Africa CDC in a written response to questions.

“It is not credible that the supervising authority and the [AU] Assembly would publicly commend an official whom they had, in the same period, suspended or sent on leave for misconduct,” added Africa CDC.

‘Toxic work environment’

The 2023 inauguration of Africa CDC’s headquarters in Addis Ababa, financed by Beijing, highlights China’s expanding health diplomacy footprint across the Global South.
The 2023 inauguration of Africa CDC’s headquarters in Addis Ababa, which was constructed by Beijing.

Ten current and former staff told Health Policy Watch that the work environment at Africa CDC is “toxic”,  fuelled by fears that Kaseya and his inner circle will remove or reassign anyone seen to question his actions or obstruct his ambitions. 

They claim staff turnover is high and that staff are often reassigned. For example, there have been five Chiefs of Staff in less than four years. In 2024, 14 staff resigned, including the Deputy Director General and five directors. Several said poor working conditions drove them away.

One staff member said almost all staff are on annual contracts with renewals requiring the Director-General’s approval.

In August, the Nigerian-based organisation African Health Initiative Advocacy (AHIA), wrote to the AU Permanent Representatives Committee (PRC) in August asking for an independent review of “recent appointments, recruitment practices, organisational changes and staff management” at Africa CDC.

There is a “growing sense among staff that they are not adequately protected when raising legitimate concerns about institutional practices,” according to the letter, obtained by Health Policy Watch.

It claimed that staff members are “being intimidated or placed under significant pressure, with some employees reportedly reaching the point of resigning because of the working environment and the pressure they experience”. 

The organisation also flagged an increase in appointments of limited duration (ALD), made “without transparent competitive recruitment”, to fill positions of staff who did not have their contracts renewed despite performing well. It also claims that advisors have been appointed and assigned functions that are usually performed by directors and heads of departments. 

Expanding not contracting

Africa CDC disputes that there has been a high turnover of senior staff, claiming that only two directors have left while seven have been recruited since Kaseya took over as DG in 2023.

“On the contrary, the institution is retaining its people and growing. It has expanded substantially over the past three years,” the body said, reporting that the staff complement has expanded from 262 staff in 2023 to 620 in 2026.

“This reflects its enlarged mandate, new functions and recruitment across the continent”, it told Health Policy Watch.

In response to criticism of arbitrary staff reassignments, Africa CDC notes: “[In] any institution that grows this fast, some colleagues change roles, some complete fixed-term contracts and some move on to other opportunities. This is normal career movement; it is not high turnover and it is not a sign of instability.” 

Only 37 staff “hold posts approved and paid for by member states”, according to CDC. The remainder of staff are funded by major donor projects, and when those end, then so do the assignments.  

For instance, a $1.1 billion five-year MasterCard Foundation grant for the “Saving Lives and Livelihoods (SLL) initiative ended in June, resulting in significant job losses. 

At the same time, the Ebola outbreak has required the deployment of new field personnel – and is likely a major factor in the creation of new positions in 2026. Africa CDC alludes to this, telling Health Policy Watch: “In an active outbreak, speed is decisive, and the ALD [appointments of limited duration] modality allows qualified personnel to be deployed quickly”. 

While several critics complained that Kaseya is appointing staff outside the agreed organogram, Africa CDC contends that “positions outside the approved structure are not irregular positions: they are a category that the rules expressly provide for, tied to partner funding”. 

In response to Health Policy Watch queries about Kaseya not allowing discussion about his decisions, Africa CDC said that “decision-making at Africa CDC is structured, collective and documented, and decisions are discussed at every level”, citing weekly, monthly, quarterly and annual staff meetings.

Standoff with African Union Tribunal

Mahmoud Ali Youssouf, Chairperson of the African Union (AU) Commission, meeting with Judge Issoufou Boureima, President of the AU Administrative Tribunal, in February 2026.

For several months, there has also been a formal standoff between the Africa CDC and the African Union Administrative Tribunal after Kaseya reassigned three regional directors (RDs) to the organisation’s headquarters in February. 

The RDs contested their removal, lodging a complaint with the Tribunal, which is an independent judicial body that settles disputes between the AU and its staff members. The Tribunal issued an order on 12 May suspending the directors’ reassignment and directing the “respondent “ (technically, the AU Chairperson) to keep them in their positions.

However, by then Kaseya had replaced the three regional directors with people he later designated as “Special Regional Representatives of the Director-General”. They had effectively taken over the functions of the RDs in West, Central and East Africa. These posts were never advertised.

On 20 July, AUC Chairperson Youssouf directed the three RDs to accept redeployment to the Africa CDC headquarters. Then on 26 October, the Tribunal also suspended that decision. 

The Tribunal has yet to rule on two contempt filings brought by the directors against the AU Chairperson, and by extension Africa CDC, for failing to implement the Tribunal’s 12 May order. 

Meanwhile, the three RDs are apparently working at home, and sources told Health Policy Watch that they have faced threats and intense pressure to withdraw their cases.

Africa CDC reiterated that the AUC Chairperson, who “exercises administrative and financial oversight of Africa CDC” in terms of the Africa CDC Statute, is responsible for handling the issue. 

‘Extravagant expenditure’, financial weaknesses

Dr Jean Kaseya.

In late October, before the circulation of the petition, an anonymous “policy brief” was sent to AU member states and Africa CDC donors.

The ‘’brief’’ is similar to a 2023 document that also made serious allegations against Kaseya’s leadership style. Claims made in the October brief include: “intimidation” of staff, the “diversion of emergency funds towards ostentatious spending, lavish travel and favours granted to close associates”.

Six current and past staff who spoke with Health Policy Watch echoed reports of excessive travel spending, saying that Kaseya “does not spare any expense” on international trips, including stays in suites typically reserved for heads of state. 

The external auditors’ letter flagged weak control of travel spending across Africa CDC, although it does not single out Kaseya directly. For example, of the $8.8 million spent on air tickets in 2025, $1.78 million (1,608 tickets) were booked late, while 298 tickets were “irregularly” requested after the date of departure, the auditor’s letter states.

Balances in Africa CDC’s books for airline travel also did not match the airlines’ own records; the difference for Ethiopian Airlines alone was $1.56 million

In September 2025, Devex reported that an advisor’s internal email had flagged “immense amounts of funds for travel and meetings” as part of the World Bank’s five-year, $100 million grant to Africa CDC. This travel was later deemed justified by the body’s auditor. 

A separate Devex report said the World Bank had raised concerns that the spending could be seen as “extravagant” and make Africa CDC look like a “travel agency”.

Campaigning conference?

CPHIA 2025’s opening ceremony in Durban.

The CDC governing board meeting on 22 November falls on the eve of the International Conference on Public Health in Africa (CPHIA), Africa CDC’s flagship event. Insiders see the conference as a showcase event for Kaseya’s reappointment campaign. 

Some 30,000 delegates are expected, according to Kaseya’s on X on 2 November, despite the fact that Addis Ababa, the host city, only has around 25,000 hospitality beds. 

The projected budget for the conference is said to run to several million dollars, but it is unclear who is funding it. 

“For CPHIA 2026, [host country] Ethiopia is making a major contribution, including in-kind support, and these are not ours to quantify or to disclose,” Africa CDC told Health Policy Watch, when asked about the conference’s financial backers.

It added that fees from exhibitions, side events and registration were helping to cover costs, and it did not have “a CPHIA budget, as such”. 

However, Africa CDC’s Quarter 3 Review Meeting Report, presented to staff on 15 October and shared with Health Policy Watch, reports that “$36.5 million in funding requests was pending” for CPHIA, while only “around $400,000 in cash and $75,000 in kind” had been secured.

Several iNGOs were also approached to help sponsor people to attend the conference, and each was asked to contribute over a million dollars, according to a source.

Meanwhile, young people who were awarded fellowships have complained that some had their fellowships revoked. However, Africa CDC said 12,000 young people applied, and it could only accommodate 4,000.

Following the CPHIA conference in Zambia in 2023, a special audit found that a Zambian company that won the bid to organise the conference for $618,638 was ultimately paid nearly $2.4 million, and that the invitation to bid had gone to only four companies, according to Devex.

Listing the financial flaws

The organisation’s 2025 annual report notes that “the grant portfolio directly managed by Africa CDC grew from $52m in 2022 to $463m in 2025, with portfolio diversification over 66 active grants”. 

Philanthropies contribute the bulk of Africa CDC’s revenue (52%), with the remainder being made up by the World Bank (21%), African Development Bank (6%), governments (8%),  Gavi, the Vaccine Alliance (3%), The Global Fund to Fight AIDS, Tuberculosis and Malaria (1%), European Union (4%), and other partners (5%).

(Source: Africa CDC Annual Report 2025)

Health Policy Watch asked Africa CDC for a copy of its latest audited financial statements, but Kamenga said the organisation had no single audit for its entire budget, but rather had “seven audits this year alone”.

The external auditors’ financial management letter, dated 27 May 2026 and covering the year to 31 December 2025, gives no overall budget figure either, but reports a cash balance of $52.9 million at the end of 2025. 

The World Bank’s $100 million over five years is the largest. Three years into the grant, Africa CDC had received $44.2 million and spent $39.8 million.

Twelve of the 49 flaws listed by the auditors are rated Grade 1, the most serious. These include $23.5 million in 2,013 bank reconciliation items that have not been cleared; spending against activities with no budget; no internal audit in 2025; and about $2.3 million of African Development Bank (AfDB) funded spending not recorded in Africa CDC’s accounts because the bank paid suppliers directly.

The auditors also flagged slow spending of World Bank and Gavi grants, and $5.3 million in a World Bank COVID-19 account that had been inactive since September 2025, with no decision on whether to use, reprogramme or return it.

Meanwhile, internal reports of spending for 2026 reveal different budget chronologies for this year. In one recent presentation to staff, seen by Health Policy Watch, the 2026 budget was $74.4 million, and $55.4 million had been spent by 9 September.

Another internal finance document, also seen by Health Policy Watch, put the body’s total revenue for this year, including grants, Ebola funding and the Africa Epidemics Fund, at $147.7 million.  

There is no published budget, and the 2025 annual report refers only to the “portfolio’ of $463 million, likely multi-year grant commitments. 

Africa CDC’s 2026 budget, as presented to staff in October.

History of accusations

Shortly after Kaseya’s appointment to lead Africa CDC in February 2023, the Presidency of the Democratic Republic of Congo (DRC) hailed it as a “great diplomatic victory and recognition of Congolese competence on a global scale”, adding that the appointment was “the epilogue of a long, secret diplomatic battle waged for six months by President Félix Tshisekedi”.

But a few months after Kaseya’s term started in 2023, a group calling itself the African Union Leadership Focus Group levelled similar claims against Kaseya as those made in the recent “policy brief”, including the “abuse and threatening of staff” and a “clear lack of leadership”, according to Devex. Africa CDC described the allegations as “unverified and baseless” at the time.

Previously, Devex reported on clashes between Kaseya and his former employer, the Clinton Health Access Initiative (CHAI), which decided not to renew his contract after two years as its country director in the DRC.

Additional reporting by K. Rifat Hossain.

Image Credits: DRC Presidency, Africa CDC, African Union, African Union, Africa CDC.

Indonesia’s Ministry of Health in Jakarta, which has mounted a sweeping diplomatic defence of Sadikin’s WHO bid.
Indonesia’s Ministry of Health in Jakarta, which has mounted a sweeping diplomatic defence of Sadikin’s WHO bid.

Jakarta has mounted a formal defence of Health Minister Budi Gunadi Sadikin’s WHO bid to become Director-General and the internal reforms he undertook as Health Minister, curbing the powers of Indonesia’s powerful health and medical associations. The rebuttal came after a coalition of Indonesian civil society groups protested his expansion of state control over medical training and standards in a petition to all of WHO’s member states, the focus of an exclusive report by Health Policy Watch. Meanwhile, some legal scholars see merit in his reforms. 

GENEVA – Indonesia has circulated a sweeping diplomatic rebuttal to World Health Organization member states, defending Health Minister Budi Gunadi Sadikin against domestic allegations of authoritarian governance.

In the 14-page filing, Jakarta portrays Sadikin as an executive reformer who took on an entrenched medical establishment to expand public healthcare access. Addressed to the WHO Executive Board and all Geneva delegations, and forwarded to Health Policy Watch, the document responds to a 4 November objection from the Coalition for Health Justice.

Ahead of the first candidate interviews in November, the coalition of medical and civil society groups alleged retaliation against outspoken critics, hospital revenue targets, and mounting judicial rebuffs.

Officials brand several of the coalition’s allegations “disinformation”, insisting the selection of the next WHO leader must “not be an extension of domestic political contestation.” Local policy battles, Jakarta argues, must not derail an objective assessment of Sadikin’s executive qualifications.

Breaking a medical guild to fix a 65,000-doctor deficit

Indonesia's Health Minister Budi Gunadi Sadikin was nominated as candidate for the WHO DG election
Indonesia’s Health Minister Budi Gunadi Sadikin was nominated as a candidate for the WHO DG election

To justify dismantling the powers of Indonesia’s medical establishment, Jakarta points to a stark domestic arithmetic: a projected deficit of nearly 65,000 specialists by 2032.

Sadikin’s signature 2023 Omnibus Health Law stripped professional associations of exclusive licensing powers. To bypass university bottlenecks, it established a hospital-based training pathway designed to “complement, not replace” existing programmes, the filing states.

The ministry contends that medical collegiums long lacked genuine independence. Before the 2023 overhaul, collegiums were “subordinate to or part of medical organizations or associations” and “not accountable to the public,” the filing argues. Leadership was appointed “without a transparent process,” while specialist trainees “had to pay a huge amount of tuition to the universities,” officials add.

In practice, that historical structure concentrated authority within the Indonesian Medical Association (IDI) and university medical faculties.

Medical deans and faculty fiercely resisted the overhaul, warning that bypassing university oversight compromised clinical standards and patient safety. In June 2025, 372 professors publicly declared a lack of confidence in Sadikin’s leadership.

While the health ministry points to the historical control of collegiums by medical associations to justify its restructuring, IDI did not sign the coalition’s letter. It was one of five professional bodies whose challenge to the 2023 law was rejected by the Constitutional Court. IDI did not respond to requests for comment by the time of publication.

Courtroom defeats and regulatory fallout

The Indonesian Supreme Court in Jakarta, where judges recently dealt major legal setbacks to Health Minister Sadikin’s reforms.
The Indonesian Supreme Court in Jakarta, which recently dealt major legal setbacks to Health Minister Sadikin’s reforms.

In its Geneva filing, the ministry downplays the Constitutional Court’s ruling on collegium independence against its reforms, characterising the verdict as a narrow procedural adjustment. That decision “merely stripped” the ministry of powers to select board candidates and establish new collegiums, leaving the existing system intact, Jakarta contends.

The Court itself held that collegiums must operate independently as part of the Health Council, answering to the President as head of state.

While the government maintains regulatory adjustments are underway, its submission omits the Supreme Court’s sweeping October ruling. That decision struck down 70 provisions, ending the minister’s sole authority over appointments to the Health Council, the collegiums and the Professional Disciplinary Council.

Under Supreme Court orders, the government has 90 days from receiving the ruling to revoke those provisions, after which they lose legal force automatically – a window likely to close around the time of the WHO Executive Board’s January session.

The ministry did not respond to questions from Health Policy Watch regarding compliance with that timeline.

Contested transfers and courtroom pushback

The RSCM Kencana wing of Jakarta’s flagship public hospital.
The RSCM Kencana wing of Jakarta’s flagship public hospital.
Outspoken critic Prof Zainal Muttaqin.
Outspoken critic Prof Zainal Muttaqin.

Jakarta rejects allegations of a systematic crackdown on dissent as “disinformation,” citing routine rotations of roughly 150 civil servant physicians across ministry hospitals since 2024. Officials label the coalition’s accounts of dismissals involving outspoken critics Prof Zainal Muttaqin and Dr Rizky Adriansyah equally unfounded. Both were part-time physicians on temporary contracts, the filing notes, though it offers no explanation for why their contracts ended.

The ministry also disputes claims regarding Prof Budi Santoso, who was removed as medical dean at Universitas Airlangga after criticising reforms. University rectors, not the health minister, control faculty posts, officials note, pointing out that his 3 July 2024 dismissal was revoked six days later.

Yet that narrative of administrative routine faces judicial pushback. The government is currently fighting to overturn a major legal victory won by prominent dissenting paediatrician Dr Piprim Basarah Yanuarso.

On 7 September, the Supreme Court annulled a decree transferring Yanuarso from Jakarta’s flagship Dr Cipto Mangunkusumo National General Hospital (RSCM) to Fatmawati General Hospital. The reassignment followed his vocal opposition to government moves placing the independent medical collegium under ministerial control.

The ministry acknowledges the court defeat, but describes the reassignment as a routine transfer an hour’s drive away. It is now challenging the verdict through an extraordinary judicial review.

Officials maintain that Yanuarso’s subsequent civil service dismissal remains legally valid, citing unexcused absence rules. The ministry argues he accepted the dismissal by applying to withdraw his pension funds in July without lodging a formal challenge. The Supreme Court ruling concerned the transfer, not the dismissal itself.

The coalition did not respond to requests for comment regarding the ministry’s rebuttal.

Executive control or guild protectionism?

Georgetown law professor Lawrence Gostin.
Georgetown law professor Lawrence Gostin.

While the civil society coalition views ministry control of the collegiums as authoritarian overreach, there is some merit to Sadikin’s reforms, according to Georgetown global health law professor Lawrence Gostin. High-functioning systems like Britain and the United States routinely separate professional advocacy from public governance, placing licensing, hospital budgets, and statutory oversight under government authority rather than private guilds, he explained.

“Thus, it is admirable that Health Minister Budi [Sadikin] centralised these functions,” Gostin told Health Policy Watch, responding to a query. “So long as he governs well, this is a benefit, not a detriment.”

That endorsement, however, hinges on scientific integrity.

“By governing well, I mean developing standards through science in ways that are transparent and accountable,” Gostin noted, cautioning that professional societies must step in whenever political leaders abandon scientific evidence.

He also cautioned against viewing judicial rebuffs as definitive proof of wrongdoing, arguing that legal challenges must be weighed against the broader public interest.

“If Budi is genuinely seeking to follow the rule of law, the critique lacks merit,” Gostin added.

The corporate turnaround pitch

Satellite image from 14 October 2026 shows wildfire smoke billowing across Borneo, driving over 433,000 respiratory cases.
Satellite image from 14 October 2026 shows wildfire smoke billowing across Borneo, driving over 433,000 respiratory cases.

For domestic critics, however, Sadikin’s governance vision has been shaped less by public health principles than by his corporate approach. The coalition sees a commercial banker imposing corporate logic on a sector that demands social protection.

Responding to this criticism, Jakarta leans directly into that financial pedigree, pitching executive management as a vital asset for global health governance. The filing firmly rejects claims that a private-sector background violates WHO criteria requiring proven leadership.

The government notes that WHO Director-General Dr Tedros Adhanom Ghebreyesus holds no medical licence, pointing to non-physician ministers in Britain and Singapore. Yet that comparison glosses over Tedros’s background as a trained public health immunologist, contrasting with Sadikin’s career in commercial banking.

To underscore Sadikin’s executive record, Jakarta points to broad reforms across digital health, infrastructure, and disease prevention. During his tenure, Sadikin oversaw the rollout of 453 million COVID-19 vaccine doses, while childhood stunting dropped from 24.4% to 19.8%. Indonesia’s 2022 G20 presidency also helped launch the World Bank-hosted Pandemic Fund.

The filing also defends his emergency crisis management during recent wildfire haze across Sumatra and Borneo. While confirming 433,162 acute respiratory infections across seven provinces, officials point to an aggressive response that deployed 815 clean-air “oxygen houses” and 1.7 million masks.

Corporate metrics in public hospitals

Aerial view of Jakarta’s flagship Dr Cipto Mangunkusumo National General Hospital (RSCM), central to debates over commercial hospital targets.
Aerial view of Jakarta’s flagship Dr Cipto Mangunkusumo National General Hospital (RSCM), central to debates over commercial hospital targets.

Jakarta firmly rejects allegations that this balance-sheet mindset has commercialised state medicine and that state facilities have prioritised revenue targets over vulnerable patients.

Responding to criticism of a 2024 directive that set hospital revenue targets, the ministry argues that several flagship facilities historically faced chronic deficits. Before 2021, some hospitals were “on the verge of collapse due to mounting debts,” prompting reforms to “root out corruption and nepotism”, the filing states.

That overhaul, officials add, “annoyed many senior physicians, some even participate in the Coalition of Health Justice.”

Jakarta’s flagship hospital spent $85 million last year – representing almost 90% of its profit – subsidising underprivileged, uninsured, and under-covered patients, the ministry reports. Revenue generated from executive and premium suites directly funds those cross-subsidies, officials argue.

The filing also addresses the death of Yurizal Tri Chaerawan, a BPJS-insured patient who reportedly died following an eight-hour emergency room wait. While critics cite the tragedy as evidence of capacity rationing, the government focuses strictly on his clinical condition.

Citing RSCM logs, officials told Geneva delegates that Yurizal required a specialised High Care Unit rather than a standard bed. That unit was operating at capacity, and the patient had severe underlying comorbidities, including malignancy, requiring palliative care.

Genomic data guardrails

The debate over commercial interests also shadows Sadikin’s technological flagship: the Biomedical and Genome Science Initiative.

Critics warn that sequencing population DNA alongside foreign biotech firms compromises national bio-sovereignty. The coalition specifically flags partnerships with global sequencing giants, alleging insufficient safeguards over valuable genetic IP.

Jakarta firmly rejects those concerns, stressing that genomic data remains sovereign state property under ministerial decree. External partners, the filing argues, receive strictly limited access.

In its technical defence, the ministry outlines a “data visitation” model built on a Trusted Research Environment, which lets authorised researchers analyse genomic data inside a secure platform without downloading or transferring raw data outside it.

The Executive Board Test

The WHO Executive Board in Geneva, where Indonesia argues domestic political disputes must not derail Sadikin’s candidacy.
The WHO Executive Board in Geneva, where Indonesia argues domestic political disputes must not derail Sadikin’s candidacy.

As the coalition directly challenges Sadikin’s eligibility as a candidate for WHO Director-General, alleging his domestic record fails core public health leadership criteria, Indonesia’s health ministry firmly pushes back on that assessment. In its submission, Jakarta warns delegations that multilateral appointments must not become extensions of domestic political disputes.

In Geneva, domestic judicial friction and workforce alienation rarely derail a Director-General bid, according to Lawrence Gostin, a leading global health law scholar at Georgetown University.

“It should not mean anything,” Gostin said. Multilateral delegations, he explained, weigh a candidate’s strategic capacity and diplomatic stature over local political friction.

Formal dossiers from both sides are now circulating among Geneva delegations. Sadikin is one of seven candidates WHO announced on 29 October. The 34-member Executive Board will shortlist and interview candidates at its 25 January to 2 February session and nominate up to three, before the World Health Assembly appoints the new Director-General in May.

See related story:

EXCLUSIVE: Indonesian Civil Society Coalition Challenges Sadikin’s Bid to Become WHO Director General

Image Credits: Kementerian Kesehatan Republik Indonesia, Gedung Mahkamah Agung RI, RSCM, Felix Sassmannshausen/HPW, Georgetown Law, European Space Agency (ESA).